Drugs that contain Istradefylline

1. List of Nourianz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7541363 KYOWA KIRIN Microcrystal
Nov, 2024

(1 year, 7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7727994 KYOWA KIRIN Methods of treating patients suffering from movement disorders
Jan, 2023

(2 months ago)

US7727993 KYOWA KIRIN Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy
Jan, 2023

(a month ago)

US8318201 KYOWA KIRIN Method of stabilizing diarylvinylene compound
Sep, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 27, 2024

NCE-1 date: 2023-08-28

Market Authorisation Date: 27 August, 2019

Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives said l-dopa therapy

Dosage: TABLET;ORAL

More Information on Dosage

NOURIANZ family patents

11

United States

10

Japan

8

Korea, Republic of

6

European Union

5

China

4

Australia

4

Canada

4

Spain

2

Portugal

2

Hungary

1

Taiwan, Province of China

1

Turkey

1

Colombia

1

EA

1

Austria

1

Mexico

1

Argentina

1

Brazil

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in